XML 31 R15.htm IDEA: XBRL DOCUMENT v3.25.4
EARNINGS PER SHARE
 12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the years ended December 31, 2025, 2024, and 2023 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share recorded in those periods.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Year Ended December 31,
202520242023
Stock option awards697,024854,5451,214,560
Restricted stock awards575,070376,743340,331
Performance stock unit awards354,696286,881—
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202520242023
Numerator:  
Net income (1)$207,585 $211,823 $267,090 
Denominator:  
Weighted average number of common shares outstanding162,099 171,567 178,973 
Earnings per Common Share:
Earnings per common share, basic$1.28 $1.23 $1.49 
(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions, for further discussion.
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202520242023
Numerator:  
Net income (1)$207,585 $211,823 $267,090 
Denominator:  
Weighted average number of common shares outstanding162,099 171,567 178,973 
Effect of dilutive securities1,266 1,278 1,402 
Weighted average number of common shares outstanding, diluted163,365 172,845 180,375 
Earnings per Common Share:
Earnings per common share, diluted$1.27 $1.23 $1.48 
(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions, for further discussion.